Is HIMS stock the best buy in March 2026?

Core Viewpoint - The recent partnership with Novo Nordisk has alleviated significant legal risks for Hims & Hers Health, leading to a sharp rebound in its stock price and opening up new market opportunities for the company [1][3][10]. Group 1: Legal and Market Developments - The lawsuit from Novo Nordisk, which posed a major threat to Hims due to its compounded semaglutide products, has been dropped, allowing Hims to offer branded treatments like Ozempic and Wegovy [1][2][3]. - Hims' stock has increased by 40% in a single day, trading above $22, reflecting investor optimism about the company's growth potential [2][3]. Group 2: Financial Performance - Hims reported a revenue of $2.35 billion for 2025, marking a 59% year-over-year increase, with a net income of $128 million [5]. Group 3: Expansion Strategies - The company is pursuing international expansion by acquiring Eucalyptus, a digital health platform, which will enhance its ability to distribute weight-loss therapies across various international markets [6]. - Hims could become a key distribution partner for multiple GLP-1 manufacturers, positioning itself as a significant player in the digital health space for metabolic drugs [7]. Group 4: Future Outlook - The success of Hims will depend on its ability to scale its subscriber platform, secure additional drug partnerships, and maintain its growth trajectory [10]. - Investor sentiment remains positive, driven by strong revenue growth and expanded access to blockbuster treatments, suggesting that Hims shares are worth monitoring in the near future [11].